ConductScience.org, home

Paper950592

Pharmacokinetics of isoniazid metabolism in man.

Ellard GA and 1 other. J Pharmacokinet Biopharm, 1976. Cited by 182 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. Pharmacokinetics of isoniazid metabolism in man. Papers, record 950592. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/950592

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Pharmacokinetics of isoniazid metabolism in man.
PubMed
Journal
J Pharmacokinet Biopharm
PubMed
Year
1976
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
182
iCite
Relative citation ratio, by iCite
7.32
iCite
Revised in PubMed
2019-10-21
PubMed

Authors2

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Ellard GAG A
2Gammon PTP T

Source PubMed

Topics6

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
IsoniazidMajor topic
Acetylation
Glycine
Humans
Isonicotinic Acids
Kinetics

Source PubMed

References29

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
1773,583Variations between individuals and populations in the acetylation of isoniazid and its significance for the treatment of pulmonary tuberculosis.Clin Pharmacol Ther1976https://conductscience.org/library/papers/773583PubMed
26,032,052Kinetic considerations relating to the accrual and elimination of drug metabolites.Br J Pharmacol Chemother1967https://conductscience.org/library/papers/6032052PubMed
34,116,545General considerations in the choice and management of regimens of chemotherapy for pulmonary tuberculosis.Bull Int Union Tuberc1972https://conductscience.org/library/papers/4116545PubMed
45,916,738Comparative studies on the metabolism of isoniazid and isoniazid hydroazones in the dog.Arch Int Pharmacodyn Ther1966https://conductscience.org/library/papers/5916738PubMed
513,789,848A study of the renal clearances, metabolic inactivation rates, and serum fall-off interaction of isoniazid and paraminosalicylic acid in man.Am Rev Respir Dis1961https://conductscience.org/library/papers/13789848PubMed
64,834,616Pharmacokinetic studies with an isoniazid slow-releasing matrix preparation.Am Rev Respir Dis1974https://conductscience.org/library/papers/4834616PubMed
74,452,938The influence of bacterial gut hydrolysis on the fate of orally administered isonicotinuric acid in man.J Pharmacokinet Biopharm1974https://conductscience.org/library/papers/4452938PubMed
85,349,625A study of the availability of six commercial formulations of isoniazid.Clin Pharmacol Ther1969https://conductscience.org/library/papers/5349625PubMed
95,075,259The determination of isoniazid and its metabolites acetylisoniazid, monoacetylhydrazine, diacetylhydrazine, isonicotinic acid and isonicotinylglycine in serum and urine.Biochem J1972https://conductscience.org/library/papers/5075259PubMed
104,774,936The determination of the acetylator phenotype of tuberculosis patients in Czechoslovakia using sulphadimidine.Tubercle1973https://conductscience.org/library/papers/4774936PubMed
115,973,152Kinetics of competitive inhibition of salicylic acid conjugation with glycine in man.Biochem Pharmacol1966https://conductscience.org/library/papers/5973152PubMed
124,875,398Genetic factors in relation to drugs.Annu Rev Pharmacol1968https://conductscience.org/library/papers/4875398PubMed
134,109,735Pharmacology of some slow-release preparations of isoniazid of potential use in intermittent treatment of tuberculosis.Lancet1972https://conductscience.org/library/papers/4109735PubMed
145,855,885Studies on the metabolic basis for the genetically determined capacities for isoniazid inactivation in man.J Pharmacol Exp Ther1965https://conductscience.org/library/papers/5855885PubMed
1514,046,608ASPECTS OF THE METABOLISM OF ISONIAZID AND ACETYLISONIAZID IN THE HUMAN AND THE DOG.J Med Pharm Chem1962https://conductscience.org/library/papers/14046608PubMed
164,556,778Isoniazid and psuedocholinesterase polymorphisms.Fed Proc1972https://conductscience.org/library/papers/4556778PubMed
171,216,339Determination of the acetylator phenotype using matrix isoniazid.Tubercle1975https://conductscience.org/library/papers/1216339PubMed
185,263,687Genetic variations in the acetylation of isoniazid and other drugs.Ann N Y Acad Sci1968https://conductscience.org/library/papers/5263687PubMed
195,435,232Rapid determination of isonicotinic acid hydrazide in whole blood with 2,4,6-trinitrobenzenesulphonic acid.Clin Chim Acta1970https://conductscience.org/library/papers/5435232PubMed
201,149,365Increased incidence of isoniazid hepatitis in rapid acetylators: possible relation to hydranize metabolites.Clin Pharmacol Ther1975https://conductscience.org/library/papers/1149365PubMed

See all 29 references

Cited by59

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 182 citations.

PMIDTitleJournalYearIn PapersSource
40,893,955Carbamate Prodrugs Restrict In Vivo Metabolism and Improve the Pharmacokinetics of Isoniazid.ACS Cent Sci2025https://conductscience.org/library/papers/40893955PubMed
40,741,006A scoping review about smoking, smoking cessation and their effects on anti-tuberculosis agents: insights into drug metabolisms, safety, and effectiveness.Front Pharmacol2025https://conductscience.org/library/papers/40741006PubMed
39,959,342Clinical perspectives of isoniazid-induced liver injury.Liver Res2021https://conductscience.org/library/papers/39959342PubMed
39,758,904A turn-on fluorescent probe containing a β-ketoester moiety for the selective detection of intracellular hydrazine.RSC Adv2025https://conductscience.org/library/papers/39758904PubMed
39,364,056Isoniazid-historical development, metabolism associated toxicity and a perspective on its pharmacological improvement.Front Pharmacol2024https://conductscience.org/library/papers/39364056PubMed
38,584,604Effect of NAT2, GSTM1 and CYP2E1 genetic polymorphisms on plasma concentration of isoniazid and its metabolites in patients with tuberculosis, and the assessment of exposure-response relationships.Front Pharmacol2024https://conductscience.org/library/papers/38584604PubMed
36,200,885The Changing Paradigm of Drug-Resistant Tuberculosis Treatment: Successes, Pitfalls, and Future Perspectives.Clin Microbiol Rev2022https://conductscience.org/library/papers/36200885PubMed
36,069,614Effects of Enzyme Induction and Polymorphism on the Pharmacokinetics of Isoniazid and Rifampin in Tuberculosis/HIV Patients.Antimicrob Agents Chemother2022https://conductscience.org/library/papers/36069614PubMed
36,061,038Patient-centered mobile tuberculosis treatment support tools (TB-TSTs) to improve treatment adherence: A pilot randomized controlled trial exploring feasibility, acceptability and refinement needs.Lancet Reg Health Am2022https://conductscience.org/library/papers/36061038PubMed
35,707,778Genetic Variants and Drug Efficacy in Tuberculosis: A Step toward Personalized Therapy.Glob Med Genet2022https://conductscience.org/library/papers/35707778PubMed
35,510,229Defensive role of Nigella sativa against antituberculosis drugs induced renal toxicity.Toxicol Res (Camb)2022https://conductscience.org/library/papers/35510229PubMed
35,497,447A sensitive and selective fluorescent probe for hydrazine with a unique nonaromatic fluorophore.RSC Adv2020https://conductscience.org/library/papers/35497447PubMed
34,905,153Drug-Drug Interaction Potential with Once-Weekly Isoniazid/Rifapentine (3HP) for the Treatment of Latent Tuberculosis Infection.Clin Pharmacokinet2022https://conductscience.org/library/papers/34905153PubMed
34,635,182Application of modified Michaelis - Menten equations for determination of enzyme inducing and inhibiting drugs.BMC Pharmacol Toxicol2021https://conductscience.org/library/papers/34635182PubMed
33,537,010Biochemical Characterization of Arylamine N-acetyltransferases From Vibrio vulnificus.Front Microbiol2020https://conductscience.org/library/papers/33537010PubMed
33,106,268Acetylation of Isoniazid Is a Novel Mechanism of Isoniazid Resistance in Mycobacterium tuberculosis.Antimicrob Agents Chemother2020https://conductscience.org/library/papers/33106268PubMed
31,964,788N-Acetyltransferase 2 Genotypes among Zulu-Speaking South Africans and Isoniazid and N-Acetyl-Isoniazid Pharmacokinetics during Antituberculosis Treatment.Antimicrob Agents Chemother2020https://conductscience.org/library/papers/31964788PubMed
31,591,118A Pharmacology Perspective of Simultaneous Tuberculosis and Hepatitis C Treatment.Antimicrob Agents Chemother2019https://conductscience.org/library/papers/31591118PubMed
30,767,706Effects of genetic variability on rifampicin and isoniazid pharmacokinetics in South African patients with recurrent tuberculosis.Pharmacogenomics2019https://conductscience.org/library/papers/30767706PubMed
30,545,003Optimization and Validation of a Chromatographic Method for the Quantification of Isoniazid in Urine of Tuberculosis Patients According to the European Medicines Agency Guideline.Antibiotics (Basel)2018https://conductscience.org/library/papers/30545003PubMed

See all 59 cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/950592

GET https://conductscience.org/api/papers/v1/950592/references?page=2